Research Guide

Ms. Zhu never imagined that at the age of 84, she would undergo such a "record-breaking" surgery. Doctors removed her entire pancreas, spleen, and gallbladder, reconstructed her gastrointestinal tract and blood vessels, and simultaneously performed an autologous islet transplantation.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

Orlando, USA, Dec 6-9, 2025 – The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

CAR-T therapy, the 4th major cancer treatment, engineers patient's T cells to target cancers. Highly effective for blood cancers like leukemia & lymphoma. Promising for solid tumors & non-cancer diseases. Faces challenges like cost & side effects, but research is advancing rapidly.

Lu Daopei Hospital's dual-target CAR-T saves critically ill international DLBCL patient! A 60-year-old Egyptian with massive abdominal tumor & TP53 mutations achieved remarkable recovery after CD19/CD22 CAR-T + radiotherapy. From unable to sit to walking out smiling.

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.

Gynecomastia is the benign enlargement of male breast tissue, caused by estrogen-androgen imbalance. Common in infants, teens, and older men, it can involve glandular tissue, fat, or both. While often a cosmetic concern, it may cause distress. Treatments include medication or surgery (liposuction/excision) if persistent. Effective correction is achievable.

Gynecomastia: Understanding Male Breast Development Gynecomastia, or male breast enlargement, stems from estrogen-testosterone imbalance. Causes include puberty, obesity, medications, or underlying conditions. Diagnosis involves physical exams, hormone tests, or ultrasound. Treatments range from addressing root causes to medication or minimally invasive surgery. Many seek correction for confidence. Consult a specialist for personalized care.

Relapsed/Refractory Diffuse Large B-Cell Lymphoma - A Breakthrough in CD20 CAR-T Preemptive Therapy. the team of Directors Ke Xiaoyan and Hu Kai from the Department of Lymphoma and Myeloma at Beijing Gobroad Hospital published a study titled "CD20 CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19 CAR-T" in the journal Transplant and Cellular Therapy.